You are here: Industry Insights > NICE

News List

NICE hits Keytruda with ‘no’ for urothelial cancer pharmatimes
March 13, 2020
The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending against the routine use of Keytruda (pembrolizumab) locally advanced or metastatic urothelial carcinoma.
Ajovy bags NICE approval pharmatimes
March 13, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Teva’s Ajovy for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.
NICE, Health Technology Wales announce new partnership pharmatimes
March 12, 2020
The National Institute for Health and Care Excellence (NICE) has announced a new collaboration with Health Technology Wales.The two organisations have detailed plans to work together on planning and information sharing over the assessment of medical techn
NICE pushes Doptelet for pre-surgery liver disease treatment PharmaTimes
March 05, 2020
The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
NICE does not recommend polatuzumab vedotin to treat lymphoma europeanpharmaceuticalreview
March 03, 2020
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
Lenalidomide recommended for use with rituximab by NICE europeanpharmaceuticalreview
March 03, 2020
NICE has given its positive opinion to lenalidomide in combination with rituximab as a ‘chemotherapy-free’ treatment for lymphoma.
NICE recommends olaparib tablets for platinum-sensitive cancer patients europeanpharmaceuticalreview
January 19, 2020
NICE has recommended olaparib tablets (Lynparza, AstraZeneca) for adults with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer with a BRCA1 or BRCA2 mutation.
NICE requests more data on Keytruda for head and neck cancer treatment europeanpharmaceuticalreview
January 17, 2020
NICE has asked for more information on Keytruda (pembrolizumab) for untreated metastatic or unresectable recurrent squamous cell head and neck cancer due to uncertainty over clinical trial evidence.
NICE approves palbociclib with fulvestrant on the CDF for treatment of some breast cancers europeanpharmaceuticalreview
January 16, 2020
The NICE committee has made palbociclib with fulvestrant available on the Cancer Drug Fund for patients with hormone receptor-positive, HER2-negative, advanced breast cancer.
NICE argue for more histology-independent cancer drug evidence europeanpharmaceuticalreview
January 13, 2020
Staff at NICE have co-authored a paper which suggests that new, histology-independent cancer treatments require more clinical evidence before approval recommendation by the institution.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page